GLP-3 Retatrutide: an evidence-first deep dive

This quiz is separate from the lesson so you can finish learning first, then test what you retained.

Lesson checkpoint

GLP-3 Retatrutide: an evidence-first deep dive checkpoint

This checkpoint tests the lesson you just completed. Passing marks it complete and unlocks the next course step.

Get every question correct to pass.

1. Which three receptor systems does GLP-3 Retatrutide target?

GIP, GLP-1 and glucagonGHRH, ghrelin and insulinMelanocortin, dopamine and serotoninGLP-1 only

2. What makes the 2023 Phase 2 trial a stronger evidence artifact than a press release?

Full peer-reviewed methods, predefined endpoints and detailed results are availableIt uses more marketing languageIt guarantees future approvalIt contains no adverse-event data

3. How should 2026 Phase 3 topline results be described?

Important pivotal evidence that may still await full peer-reviewed publication and regulatory reviewAn approved prescribing labelAnecdotal evidencePreclinical evidence

4. What does GLP-3 Retatrutide's status remain as of September 2026?

InvestigationalFDA-approved for obesityApproved over the counterWithdrawn from research

5. Why can't an online vial simply inherit the clinical-trial evidence?

Identity, purity, concentration and manufacturing equivalence have not been establishedThe name on the label proves equivalenceClinical trials never verify study drugVials cannot contain peptides

PThe Pep Report

Educational information only. Not medical advice.

Personalised Guide Safety & info Research Sourcing Guide